Process Development toward DHODH Inhibitor JNJ-6665

Résumé fourni par la source

Abstract JNJ-6665 is a dihydroorotate dehydrogenase (DHODH) inhibitor progressed for first-in-human studies. We developed a convergent, chromatography-free manufacturing route leveraging a regioselective SNAr coupling of triazolone 5 and isoquinolone 10. Triazolone 5 was prepared through a safe three-step telescoped process using catalytic TBD to deliver very high purity material in 83% overall yield. Isoquinolone 10 was accessed via an elegant Pd-catalyzed α-arylation, followed by a telescoped hydrolysis/amination. Coupling of 5 and 10 was performed using a phase-transfer catalyst, affording JNJ-6665 in 91–92% isolated yield and 99.2–99.6 area% purity after final debenzylation, enabling robust GMP campaigns to support GLP toxicology and FIH clinical studies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.